Group One Trading
BCRX icon

Group One Trading’s BioCryst Pharmaceuticals BCRX Stock Holding History

Group One Trading’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$515K Sell
54,100
-277,200
-84% -$2.15M ﹤0.01% 3316
2025
Q4 		$2.58M Buy
331,300
+147,300
+80% +$1.06M ﹤0.01% 2046
2025
Q3 		$1.4M Sell
184,000
-166,100
-47% -$1.38M ﹤0.01% 2677
2025
Q2 		$3.14M Sell
350,100
-144,300
-29% -$1.34M 0.01% 1713
2025
Q1 		$3.71M Sell
494,400
-297,600
-38% -$2.4M 0.01% 1307
2024
Q4 		$5.96M Sell
792,000
-103,300
-12% -$784K 0.01% 1042
2024
Q3 		$6.8M Buy
895,300
+114,700
+15% +$872K 0.02% 828
2024
Q2 		$4.82M Buy
780,600
+384,900
+97% +$2.12M 0.02% 823
2024
Q1 		$2.01M Sell
395,700
-656,000
-62% -$3.69M 0.01% 1477
2023
Q4 		$6.3M Buy
1,051,700
+304,700
+41% +$1.77M 0.02% 959
2023
Q3 		$5.29M Buy
747,000
+12,200
+2% +$87.7K 0.02% 914
2023
Q2 		$5.17M Sell
734,800
-37,300
-5% -$299K 0.02% 934
2023
Q1 		$6.44M Sell
772,100
-533,500
-41% -$5.14M 0.02% 700
2022
Q4 		$15M Sell
1,305,600
-61,400
-4% -$766K 0.03% 518
2022
Q3 		$17.2M Sell
1,367,000
-61,100
-4% -$786K 0.03% 457
2022
Q2 		$15.1M Sell
1,428,100
-198,000
-12% -$2.04M 0.02% 612
2022
Q1 		$26.4M Sell
1,626,100
-117,300
-7% -$1.88M 0.03% 482
2021
Q4 		$24.1M Buy
1,743,400
+464,100
+36% +$6.14M 0.02% 591
2021
Q3 		$18.4M Buy
1,279,300
+38,100
+3% +$601K 0.02% 662
2021
Q2 		$19.6M Buy
1,241,200
+354,900
+40% +$4.82M 0.02% 643
2021
Q1 		$9.01M Buy
886,300
+583,100
+192% +$6.01M 0.01% 1017
2020
Q4 		$2.26M Sell
303,200
-21,700
-7% -$112K ﹤0.01% 1946
2020
Q3 		$1.12M Sell
324,900
-1,400
-0.4% -$6K ﹤0.01% 2087
2020
Q2 		$1.55M Buy
326,300
+67,300
+26% +$269K 0.01% 1652
2020
Q1 		$518K Buy
259,000
+211,400
+444% +$582K ﹤0.01% 2026
2019
Q4 		$164K Buy
47,600
+11,100
+30% +$27.9K ﹤0.01% 3308
2019
Q3 		$105K Sell
36,500
-119,700
-77% -$372K ﹤0.01% 3522
2019
Q2 		$592K Buy
156,200
+144,600
+1,247% +$870K 0.01% 1993
2019
Q1 		$94K Sell
11,600
-16,800
-59% -$144K ﹤0.01% 3212
2018
Q4 		$229K Buy
28,400
+7,200
+34% +$56K ﹤0.01% 2579
2018
Q3 		$162K Buy
21,200
+17,000
+405% +$114K ﹤0.01% 3166
2018
Q2 		$24K Sell
4,200
-12,800
-75% -$70.5K ﹤0.01% 4300
2018
Q1 		$81K Buy
17,000
+4,900
+40% +$25.2K ﹤0.01% 3372
2017
Q4 		$59K Sell
12,100
-9,300
-43% -$45.1K ﹤0.01% 3635
2017
Q3 		$112K Sell
21,400
-222,500
-91% -$1.14M ﹤0.01% 3161
2017
Q2 		$1.36M Sell
243,900
-60,800
-20% -$370K 0.01% 1224
2017
Q1 		$2.56M Buy
304,700
+24,200
+9% +$168K 0.03% 715
2016
Q4 		$1.78M Buy
280,500
+214,900
+328% +$1.12M 0.02% 979
2016
Q3 		$289K Buy
65,600
+60,600
+1,212% +$242K ﹤0.01% 2220
2016
Q2 		$14K Sell
5,000
-5,000
-50% -$15.5K ﹤0.01% 3938
2016
Q1 		$28K Sell
10,000
-49,300
-83% -$219K ﹤0.01% 3570
2015
Q4 		$612K Buy
59,300
+1,100
+2% +$10.9K 0.01% 1644
2015
Q3 		$663K Sell
58,200
-32,700
-36% -$436K 0.01% 1551
2015
Q2 		$1.36M Buy
90,900
+75,500
+490% +$858K 0.02% 988
2015
Q1 		$139K Sell
15,400
-76,700
-83% -$794K ﹤0.01% 2654
2014
Q4 		$1.12M Buy
92,100
+67,500
+274% +$746K 0.02% 1009
2014
Q3 		$241K Sell
24,600
-39,800
-62% -$488K ﹤0.01% 2228
2014
Q2 		$821K Sell
64,400
-11,800
-15% -$115K 0.01% 1272
2014
Q1 		$806K Buy
76,200
+58,300
+326% +$622K 0.01% 1252
2013
Q4 		$136K Sell
17,900
-145,500
-89% -$921K ﹤0.01% 2766
2013
Q3 		$1.19M Buy
163,400
+120,700
+283% +$612K 0.02% 889
2013
Q2 		$66K Buy
+42,700
New +$73.7K ﹤0.01% 3184

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Group One Trading's BCRX Position: Q1 2026 in Review

Group One Trading increased its BioCryst Pharmaceuticals (BCRX) stake by 125% in Q1 2026, buying an estimated $588K and bringing the position to 136,282 shares worth $1.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2468.

Group One Trading first reported a position in BCRX in Q2 2013 and has held it in 37 quarters since. The position peaked at $1.92M in Q4 2021. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

  • Group One Trading held 136,282 shares of BioCryst Pharmaceuticals worth $1.3M as of Q1 2026.
  • Group One Trading bought 75,758 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $588K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #2468 holding.
  • Group One Trading first reported a position in BioCryst Pharmaceuticals in Q2 2013 and has held it in 37 quarters since.
  • Group One Trading's BioCryst Pharmaceuticals position peaked at $1.92M in Q4 2021.
  • 301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.